Press Releases for SHPGY

Press Releases
Impax Laboratories Commences Shipment of Generic Adderall XR® Capsules, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg
Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
Shire Initiates Two Adult ADHD Outreach Programs
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans
Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18
The Crohn's & Colitis Foundation of America and Shire Launch Virtual 'IBD March on the Hill' to Increase Funding for Digestive Disease Research
Shire begins the year with a strong performance
Shire plc: Results of the Annual General Meeting Held on April 28, 2009
Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
Publication of Shire plc's Annual Report 2008
Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced
Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Shire Announces Opening of Office in Japan
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
Shire plc: Change to Director's Details
BenchmarkJournal.Com (Complimentary) Analyst Review for CBST, PENN, WERN and SHPGY
Zacks Analyst Blog Highlights: CF Industries, Terra Industries, The Royal Bank of Scotland Group Plc, Petrobras and Shire PLC.
Semi-Annual Changes to the NASDAQ Q-50 Index - Dec 12 2008 8:41PM
Shire Plc: Investor Seminar
Confirmation of HGT Business Day - 18th November 2008
Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
Shire's New Product Portfolio Delivers Strong Quarterly Performance
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Shire Announces Results from a Multidisciplinary Analysis of the Drug Release Profiles of LIALDA(R) (mesalamine) and Asacol(R) (mesalamine) for the Treatment of Ulcerative Colitis (UC) at the American College of Gastroenterology (ACG) Meeting
Change of Name to Shire plc
Results of the Annual General Meeting Held on September 24, 2008
Acceleron Pharma Acknowledged for Positive Impact on Economic Development in Massachusetts
NEA Appoints David M. Mott as General Partner
VYVANSE(R) (lisdexamfetamine dimesylate) Now Available in U.S. Pharmacies Nationwide in Six Dosage Strengths, Allowing Physicians to Titrate to Achieve Optimal Efficacy and Tolerability in Children and Adults with ADHD
Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
Celebrity Designer and ADHD Spokesperson Ty Pennington Partners With Shire to Announce the Launch of VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD in Adults
Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire
Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced
Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
Application for Listing of Shire Limited Ordinary Shares - Jun 1 2008 5:13AM
Application for Listing of Shire Limited Ordinary Shares - May 26 2008 10:32PM
Court Approves Scheme of Arrangement - May 27 2008 1:02AM
Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW - May 27 2008 12:58AM
Shire Launches Nationwide Adult ADHD Mobile Awareness Tour - Jun 2 2008 4:06AM
Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans - Jun 2 2008 4:06AM
Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists - Jun 2 2008 4:06AM
New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months - Jun 2 2008 4:06AM
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose - Jun 2 2008 4:06AM
Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting - Jun 2 2008 4:06AM
Publication of Supplementary Prospectus
Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
New Shire Holding Company Proposal
Shire to Introduce a New UK Listed Holding Company